- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Plitidepsin – March 2020
Plitidepsin: Powder for I.V infusion 2 mg with 4 ml solvent; Aplidin®
Last updated
3 July 2020